RRoche Read More Roche’s next major breast cancer drug, Wilserdly, wins FDA nod2026-11-22 No breast cancer asset in Roche’s pipeline carries a higher valuation than giredestrant. In fact, the Swiss drugmaker’s…
RRoche Read More Roche’s Wilserdly Joins Oral SERD Market, But Adjuvant Indication Still Pending2026-11-17 Roche’s giredestrant was approved by the US FDA for the treatment of ESR1-mutated, ER+, HER2- breast cancer, joining…
RRoche Read More FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer2026-11-16 Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a…